InspireMD (NYSE:NSPR) Now Covered by Maxim Group

Maxim Group assumed coverage on shares of InspireMD (NYSE:NSPR) in a report released on Monday, MarketBeat reports. The brokerage issued a buy rating and a $6.00 price objective on the stock.

InspireMD Trading Up 3.2%

Shares of NYSE NSPR opened at $1.63 on Monday. The company has a market cap of $69.06 million, a price-to-earnings ratio of -2.17 and a beta of 0.72. InspireMD has a 12 month low of $1.51 and a 12 month high of $3.80. The stock has a 50-day moving average price of $1.83 and a two-hundred day moving average price of $2.16.

Insiders Place Their Bets

In other InspireMD news, insider Shane Thomas Gleason sold 17,593 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $1.62, for a total value of $28,500.66. Following the sale, the insider owned 1,174,664 shares in the company, valued at $1,902,955.68. This trade represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 61,194 shares of company stock valued at $99,188 in the last quarter. Company insiders own 34.06% of the company’s stock.

Institutional Investors Weigh In On InspireMD

Several hedge funds have recently added to or reduced their stakes in NSPR. Aberdeen Group plc acquired a new position in InspireMD in the 3rd quarter valued at approximately $5,979,000. Rosalind Advisors Inc. grew its stake in shares of InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the last quarter. Velan Capital Investment Management LP increased its holdings in InspireMD by 137.1% in the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after purchasing an additional 1,239,669 shares during the period. Parkman Healthcare Partners LLC raised its position in InspireMD by 97.6% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock worth $5,882,000 after purchasing an additional 1,205,328 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its position in InspireMD by 45.7% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock worth $8,137,000 after purchasing an additional 1,058,467 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

More InspireMD News

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Maxim Group initiated coverage with a “Buy” rating and a $6.00 price target (roughly +268% from the current ~ $1.63 price), which likely drove investor interest and the intraday uptick. Article Title
• Negative Sentiment: Insider Shane Thomas Gleason has sold a series of shares across mid‑January to early February (multiple filings) — a total of 61,194 shares sold between Jan. 15 and Feb. 2 at prices roughly in the $1.57–$1.66 range. While the insider still holds ~1.14M shares (valued at ~ $1.8M), the concentrated string of sales is a negative signal that may cap gains or increase short‑term volatility. SEC Filing

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.